Bright Minds Biosciences Inc. (CSE: DRUG) (NASDAQ: DRUG) (“Bright Minds” or the “Company”), a company focused on developing highly selective 5-HT2 agonists for the treatment of drug ...

On Tuesday, TD Cowen commenced coverage on Bright Minds Biosciences Inc. (NASDAQ:DRUG) with a Buy rating, indicating a positive outlook for the biotechnology company’s future. The company’s ...

Bright Minds is a biotechnology company developing innovative treatments for patients with neurological and psychiatric disorders. Our pipeline includes novel compounds targeting key receptors in ...

On Tuesday, TD Cowen commenced coverage on Bright Minds Biosciences Inc. (NASDAQ:DRUG) with a Buy rating, indicating a positive outlook for the biotechnology company’s future. The company’s stock has ...

"DBA/2 is an excellent model for understanding the effect of anti-epileptic drugs (AEDs) on the etiology of seizures,” stated Jan Torleif Pedersen, PhD, MSc, Director, Chief Science Officer, of Bright ...

Chardan views Bright Minds Biosciences as a high-risk, high-reward play despite the partially validated mechanism of action. Price Action: DRUG stock is up 4.84% at $30.43 at the last check Wednesday.

(RTTNews) - Bright Minds Biosciences (DRUG), Tuesday announced that BMB-101, its selective 5-HT2C Gq-biased agonist, completely abolished drop seizures in the DBA/2 mouse model of epilepsy.

Here's what some of Wall Street's brightest minds have to say. Barclays Barclays on Tuesday walked back its earlier call for a mild recession to hit the economy in the second half of this year.